Lon­za bags Cap­sug­el and its oral drug de­liv­ery tech for $5.5B: Biotech vet Truex named COO at Syn­log­ic

Switzer­land’s Lon­za has bagged Mor­ris­town, NJ-based Cap­sug­el for $5.5 bil­lion in a deal de­signed to make the phar­ma in­dus­try sup­pli­er a world leader in drug de­liv­ery tech and man­u­fac­tur­ing. The buy­out gives the Swiss buy­er a big role to play in the oral drug and con­sumer mar­kets. It al­so reg­is­tered as a big pre­mi­um for the own­er, KKR, the lat­est ex­am­ple that de­sir­able as­sets in bio­phar­ma are at­tract­ing big bids — which isn’t al­ways wel­come by in­vestors. Lon­za ex­pects to carve about $30 mil­lion in cost “syn­er­gies” as well as $15 mil­lion in an­nu­al tax sav­ings out of the buy­out. Cap­sug­el has 3,600 staffers work­ing in 13 fa­cil­i­ties scat­tered around the globe.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.